FTY720 FREEDOMS data
Initial study results
Media release
View the media release (English)
Fact sheets
FREEDOMS
(100 KB)
FTY720 (Oral Fingolimod)
(140 KB)
Multiple Sclerosis (MS)
(100 KB)
Novartis in MS
(100 KB)
IR presentation
Trevor Mundel, Global Head of Development
Gordon Francis, Head Clinical Science Unit, NeuroImmunology
FTY720 FREEDOMS study: Initial results
(250 KB)
Our businesses
We offer a wide range of healthcare products in pharmaceuticals, vaccines and diagnostics, generics and consumer health.